Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Meloxicam in acute episodes of soft-tissue rheumatism of the shoulder
Autore:
Vidal, L; Kneer, W; Baturone, M; Sigmund, R;
Indirizzi:
Boehringer Ingelheim Peru, Lima 100, Peru Boehringer Ingelheim Peru LimaPeru 100 r Ingelheim Peru, Lima 100, Peru Hosp Vigil Quinones, Seville, Spain Hosp Vigil Quinones Seville SpainHosp Vigil Quinones, Seville, Spain Boehringer Ingelheim, Dept Med Data Serv Biometr, Biberach, Germany Boehringer Ingelheim Biberach Germany a Serv Biometr, Biberach, Germany
Titolo Testata:
INFLAMMATION RESEARCH
, volume: 50, anno: 2001, supplemento:, 1
pagine: S24 - S29
SICI:
1023-3830(200103)50:<S24:MIAEOS>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOUBLE-BLIND; ORAL MELOXICAM; PIROXICAM; EFFICACY; SAFETY; TRIAL; OSTEOARTHRITIS; TOLERABILITY; ARTHRITIS; NAPROXEN;
Keywords:
meloxicam; rheumatoid arthritis; non-steroidal anti-inflammatory drugs;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Vidal, L Boehringer Ingelheim Peru, Av Republ Panama 2557,Apartado 3915, Lima 100, Peru Boehringer Ingelheim Peru Av Republ Panama 2557,Apartado 3915Lima Peru 100
Citazione:
L. Vidal et al., "Meloxicam in acute episodes of soft-tissue rheumatism of the shoulder", INFLAMM RES, 50, 2001, pp. S24-S29

Abstract

Objective: This double-blind, randomised trial compared the efficacy and safety of meloxicam vs piroxicam in patients with soft-tissue rheumatism of the shoulder. Subjects: 599 outpatients at 88 centres in 9 countries. Treatment andMethods: Oral meloxicam 7.5 mg, meloxicam 15 mg or piroxicam 20 mg, once-daily for 14 days. The primary efficacy endpoint was the assessment of pain on day 7 relative to day 1. Results: Once-daily treatment with meloxicam 7.5 or 15 mg was comparable to piroxicam. A significantly higher proportion of meloxicam-treated patients had pain relief within day 1 or day 3. The incidence and intensity of adverse events was comparable between the treatment groups, although fewer patients in the meloxicam groups withdrew due to adverse events. There were noapparent differences between the two meloxicam doses. Conclusions: Treatment with meloxicam was at least as effective as treatment with piroxicam, with a favourable global tolerability for both doses of meloxicam.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 02:31:05